XML 43 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Cash flows from operating activities:      
Net loss $ (26,177,000) $ (32,279,000) $ (32,451,000)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 1,630,000 933,000 855,000
Amortization of deferred financing costs and debt discount 893,000 930,000 711,000
Joint Venture acquisition obligation accretion 204,000    
Provision for doubtful accounts 1,141,000 144,000 483,000
Change in fair value of warrants (418,000) (209,000) (4,360,000)
Change in fair value of option liability (2,250,000) 340,000 740,000
Stock-based compensation 3,608,000 3,904,000 3,316,000
Equity loss from investment in joint venture 48,000 165,000 209,000
Loss on asset disposal 257,000 0 0
Gain on previously held equity interest in joint venture (4,892,000) 0 0
Gain on sale of assets (4,453,000) 0 0
Loss on debt extinguishment 708,000 0 0
Increases (decreases) in cash caused by changes in operating assets and liabilities:      
Accounts receivable (1,209,000) (1,810,000) (670,000)
Inventories (459,000) 143,000 60,000
Other current assets (24,000) (324,000) (3,000)
Other assets (854,000) (74,000) (1,206,000)
Accounts payable and accrued expenses (409,000) 1,183,000 (1,436,000)
Deferred revenues, related party (638,000) (2,882,000) (1,992,000)
Deferred revenues (1,223,000) (2,609,000) 315,000
Long-term deferred rent (46,000) 252,000 106,000
Net cash used in operating activities (34,563,000) (32,193,000) (35,323,000)
Cash flows from investing activities:      
Purchases of property and equipment (519,000) (1,204,000) (560,000)
Proceeds from Puregraft divestiture 5,000,000 0 0
License agreement termination fee (800,000)    
Cash acquired in purchase of the Joint Venture 5,000 0 0
Net cash provided by (used in) investing activities 3,686,000 (1,204,000) (560,000)
Cash flows from financing activities:      
Principal payments on long-term obligations (22,304,000) (2,692,000) (4,529,000)
Proceeds from long-term obligations 27,000,000 0 9,444,000
Debt issuance costs and loan fees (1,744,000) 0 (719,000)
Payments toward purchase of Joint Venture (221,000) 0 0
Proceeds from exercise of employee stock options and warrants and stock purchase plan 225,000 1,413,000 2,849,000
Proceeds from sale of common stock 18,000,000 24,953,000 13,286,000
Costs from sale of common stock (184,000) (1,482,000) (194,000)
Net cash provided by financing activities 20,772,000 22,192,000 20,137,000
Effect of exchange rate changes on cash and cash equivalents (106,000) 0 0
Net decrease in cash and cash equivalents (10,211,000) (11,205,000) (15,746,000)
Cash and cash equivalents at beginning of year 25,717,000 36,922,000 52,668,000
Cash and cash equivalents at end of year 15,506,000 25,717,000 36,922,000
Cash paid during period for:      
Interest 2,252,000 2,497,000 2,031,000
Final payment fee on long-term debt 1,078,000 0 419,000
Supplemental schedule of non-cash investing and financing activities:      
Fair value of warrants allocated to additional paid-in capital 949,000 0 267,000
Capital equipment lease 0 0 79,000
Fair value of intangible assets acquired 9,394,000 0 0
Fair value of tangible assets acquired 260,000 0 0
Joint venture purchase obligation 4,709,000 0 0
Fair value of previously held equity interest at acquisition date $ 4,928,000 $ 0 $ 0